Bavarian Nordic sells discount shares to help fund Covid-19 vaccine

Bavarian Nordic has completed a new round of selling equity and has raised USD 175.8m in gross proceeds, which will in part help finance the firm's Covid-19 vaccine and ease the way to new acquisitions.
Photo: Bavarian Nordic / PR
Photo: Bavarian Nordic / PR
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN

Bavarian Nordic has sold shares worth DKK 1.1bn (USD 175.8m) at DKK 223 per share, which will partly go towards financing the company's further development of the Covid-19 vaccine which the firm has in-licensed from Adaptvac.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
Must contain at least 2 characters
Must contain at least 2 characters

Get full access for you and your coworkers

Start a free company trial today

Share article

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Further reading